Nuclear Reprogramming

METHODS IN MOLECULAR BIOLOGY™

John M. Walker, SERIES EDITOR

- 337 Ion Channels: Methods and Protocols**, edited by J. D. Stockand and Mark S. Shapiro, 2006
- 336 Clinical Applications of PCR: Second Edition**, edited by Y. M. Dennis Lo, Rossa W. K. Chiu, and K. C. Allen Chan, 2006
- 335 Fluorescent Energy Transfer Nucleic Acid Probes: Designs and Protocols**, edited by Vladimir V. Didenko, 2006
- 334 PRINS and In Situ PCR Protocols: Second Edition**, edited by Franck Pellestor, 2006
- 333 Transplantation Immunology: Methods and Protocols**, edited by Philip Hornick and Marlene Rose, 2006
- 332 Transmembrane Signaling Protocols: Second Edition**, edited by Hydar Ali and Haribabu Bodduluri, 2006
- 331 Human Embryonic Stem Cell Protocols**, edited by Kursad Turksen, 2006
- 330 Nonhuman Embryonic Stem Cell Protocols, Vol. II: Differentiation Models**, edited by Kursad Turksen, 2006
- 329 Nonhuman Embryonic Stem Cell Protocols, Vol. I: Isolation and Characterization**, edited by Kursad Turksen, 2006
- 328 New and Emerging Proteomic Techniques**, edited by Dobrin Nedelkov and Randall W. Nelson, 2006
- 327 Epidermal Growth Factor: Methods and Protocols**, edited by Tarun B. Patel and Paul J. Bertics, 2006
- 326 In Situ Hybridization Protocols, Third Edition**, edited by Ian A. Darby and Tim D. Hewitson, 2006
- 325 Nuclear Reprogramming: Methods and Protocols**, edited by Steve Pells, 2006
- 324 Hormone Assays in Biological Fluids**, edited by Michael J. Wheeler and J. S. Morley Hutchinson, 2006
- 323 Arabidopsis Protocols, Second Edition**, edited by Julio Salinas and Jose J. Sanchez-Serrano, 2006
- 322 Xenopus Protocols: Cell Biology and Signal Transduction**, edited by X. Johné Liu, 2006
- 321 Microfluidic Techniques: Reviews and Protocols**, edited by Shelley D. Minton, 2006
- 320 Cytochrome P450 Protocols, Second Edition**, edited by Ian R. Phillips and Elizabeth A. Shephard, 2006
- 319 Cell Imaging Techniques, Methods and Protocols**, edited by Douglas J. Taatjes and Brooke T. Mossman, 2006
- 318 Plant Cell Culture Protocols, Second Edition**, edited by Victor M. Loyola-Vargas and Felipe Vázquez-Flota, 2005
- 317 Differential Display Methods and Protocols, Second Edition**, edited by Peng Liang, Jonathan Meade, and Arthur B. Pardee, 2005
- 316 Bioinformatics and Drug Discovery**, edited by Richard S. Larson, 2005
- 315 Mast Cells: Methods and Protocols**, edited by Guha Krishnaswamy and David S. Chi, 2005
- 314 DNA Repair Protocols: Mammalian Systems, Second Edition**, edited by Daryl S. Henderson, 2006
- 313 Yeast Protocols: Second Edition**, edited by Wei Xiao, 2005
- 312 Calcium Signaling Protocols: Second Edition**, edited by David G. Lambert, 2005
- 311 Pharmacogenomics: Methods and Protocols**, edited by Federico Innocenti, 2005
- 310 Chemical Genomics: Reviews and Protocols**, edited by Edward D. Zanders, 2005
- 309 RNA Silencing: Methods and Protocols**, edited by Gordon Carmichael, 2005
- 308 Therapeutic Proteins: Methods and Protocols**, edited by C. Mark Smales and David C. James, 2005
- 307 Phosphodiesterase Methods and Protocols**, edited by Claire Lugnier, 2005
- 306 Receptor Binding Techniques: Second Edition**, edited by Anthony P. Davenport, 2005
- 305 Protein–Ligand Interactions: Methods and Applications**, edited by G. Ulrich Nienhaus, 2005
- 304 Human Retrovirus Protocols: Virology and Molecular Biology**, edited by Tuofu Zhu, 2005
- 303 NanoBiotechnology Protocols**, edited by Sandra J. Rosenthal and David W. Wright, 2005
- 302 Handbook of ELISPOT: Methods and Protocols**, edited by Alexander E. Kalyuzhny, 2005
- 301 Ubiquitin–Proteasome Protocols**, edited by Cam Patterson and Douglas M. Cyr, 2005
- 300 Protein Nanotechnology: Protocols, Instrumentation, and Applications**, edited by Tuan Vo-Dinh, 2005
- 299 Amyloid Proteins: Methods and Protocols**, edited by Einar M. Sigurdsson, 2005
- 298 Peptide Synthesis and Application**, edited by John Howl, 2005
- 297 Forensic DNA Typing Protocols**, edited by Angel Carracedo, 2005
- 296 Cell Cycle Control: Mechanisms and Protocols**, edited by Tim Humphrey and Gavin Brooks, 2005
- 295 Immunochemical Protocols, Third Edition**, edited by Robert Burns, 2005
- 294 Cell Migration: Developmental Methods and Protocols**, edited by Jun-Lin Guan, 2005
- 293 Laser Capture Microdissection: Methods and Protocols**, edited by Graeme I. Murray and Stephanie Curran, 2005
- 292 DNA Viruses: Methods and Protocols**, edited by Paul M. Lieberman, 2005
- 291 Molecular Toxicology Protocols**, edited by Phouthone Keohavong and Stephen G. Grant, 2005

METHODS IN MOLECULAR BIOLOGY™

Nuclear Reprogramming

Methods and Protocols

Edited by

Steve Pells

Department of Gene Function and Development

Roslin Institute

Roslin, Midlothian, UK

HUMANA PRESS TOTOWA, NEW JERSEY

© 2006 Humana Press Inc.
999 Riverview Drive, Suite 208
Totowa, New Jersey 07512

www.humanapress.com

All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise without written permission from the Publisher. Methods in Molecular Biology™ is a trademark of The Humana Press Inc.

All papers, comments, opinions, conclusions, or recommendations are those of the author(s), and do not necessarily reflect the views of the publisher.

This publication is printed on acid-free paper.
ANSI Z39.48-1984 (American Standards Institute)

Permanence of Paper for Printed Library Materials.

Cover design by Patricia F. Cleary

Cover illustrations: (*Foreground*) Reprogramming of DNA methylation during mouse preimplantation development: from the two-cell stage onwards, there is passive loss of DNA methylation attributable to exclusion of the maintenance DNA methyltransferase from the nucleus; de novo methylation is evident in the inner cell mass at the blastocyst stage. The upper row shows 5-Methylcytosine staining, and the lower row shows DNA staining in the same embryo (Fig. 1, Chap. 11; *see* complete figure and caption on p. 130 and discussion on pp. 130–131). (*Background*) Piezo-assisted injection of a cumulus cell nucleus into an MII oocyte (Fig. 3, Chap. 10; *see* complete caption and discussion on pp. 122–123).

For additional copies, pricing for bulk purchases, and/or information about other Humana titles, contact Humana at the above address or at any of the following numbers: Tel.: 973-256-1699; Fax: 973-256-8341; E-mail: orders@humanapr.com; or visit our Website: www.humanapress.com

Photocopy Authorization Policy:

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Humana Press Inc., provided that the base fee of US \$30.00 per copy is paid directly to the Copyright Clearance Center at 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license from the CCC, a separate system of payment has been arranged and is acceptable to Humana Press Inc. The fee code for users of the Transactional Reporting Service is: [1-58829-379-3/06 \$30.00].

Printed in the United States of America. 10 9 8 7 6 5 4 3 2 1

eISBN 1-59745-005-7
ISSN 1064-3745

Library of Congress Cataloging-in-Publication Data

Nuclear reprogramming : methods and protocols / edited by Steve Pells.
p. ; cm. -- (Methods in molecular biology ; 325)

Includes bibliographical references and index. ISBN 1-58829-379-3 (alk. paper)

1. Cell nuclei--Transplantation--Laboratory methods.[DNLM: 1. Cell Nucleus--physiology. 2. Cell Fusion--methods. 3. Transplantation--methods. QU 350 N965 2006] I. Pells, Steve. II. Series: Methods in molecular biology (Clifton, N.J.) ; v. 325.

QH442.2.N84 2006
660.6'5--dc22

2005020464

Preface

Starting in the 1950s, Briggs and King, and later John Gurdon and colleagues, showed that the transfer of a nucleus into an enucleated amphibian oocyte reconstitutes a cell that is capable of development at least part way to mature adulthood. This body of work showed that as an animal develops, despite the apparent loss of phenotypic potential that accompanies differentiation, the cell nucleus still contains sufficient genetic information to allow the cell to behave like a zygote and undergo embryonic development. We now know that nearly every animal cell, other than such odd exceptions as mature erythrocytes or lymphocytes with rearranged antigen receptors, contains a complete complement of the genetic information required to build another copy of the animal in question. However, the vast majority of cells in the adult are terminally differentiated with limited patterns of gene expression. These patterns of gene expression are conferred by both limitation of the repertoire of transcription factors expressed by the cell, and also by the chromatin configuration of the nucleus in that cell. This “nuclear program” defines the range of genes expressed by the cell, and hence its phenotype and function. Many of the molecular modifications conferring this program, DNA methylation, for example, are inherited epigenetically; that is, their inheritance is independent of the base pair sequence of the nuclear DNA. The sum total of all epigenetic marks in a cell comprises its epigenome.

Despite the early amphibian successes, it appeared that the more differentiated the cell that donated the nucleus, the poorer the efficiency of tadpole recovery, so that adult, terminally differentiated cells were much less efficient nuclear donors than early blastula cells. Early work in mammals, using enucleated mouse zygotes, reinforced this picture and for a long time it was thought to be impossible to transform the epigenome configuration of an adult terminally differentiated cell to that of a fertilized oocyte and thus reverse the linear, one-way process of differentiation to create a pluripotent, embryonic cell. More recently, the cloning from adult somatic cells using enucleated oocytes of several mammalian species, most famously the creation of the sheep “Dolly” at the Roslin Institute in 1997, showed that reversal of this process of increasing specification is possible. Because cloning of mammalian adults is achieved by nuclear transfer, we can conclude that the nucleus of the somatic donor provides all of the genetic information required, and that the mammalian oocyte contains an activity that acts on the donor nucleus to reprogram an embryonic state. This reassignment of a cell’s nucleus from a somatic to an

embryonic program is an example of “nuclear reprogramming.” Nuclear reprogramming is a complex process involving the restructuring of the chromatin in the nucleus, remodeling of such DNA modifications as methylation, and a major change in gene expression patterns. Nuclear reprogramming is obviously a major function of the oocyte, as it combines two haploid genomes from different sources into one diploid genome and then reprograms this new genome to form a pluripotent cell that then begins development. The oocyte is thus the canonical reprogramming cell. Nuclear reprogramming can also occur after fusion of cells of different types, where (usually) the less-differentiated cell reprograms the more-differentiated cell. Since this usually results in the loss of specific differentiated functions, this phenomenon was originally called extinction. In addition, events called transdifferentiation have been described, in which cells of one, possibly well-differentiated, type appear to differentiate into cells of another lineage, sometimes one derived from a different embryonic germ layer. Trans-differentiation events also almost certainly involve some level of nuclear reprogramming to change the phenotype and potential of the cell. At present, nuclear reprogramming is largely a “black box” and many of the events involved in a reprogramming event are either completely unknown or poorly characterized. How nuclear reprogramming is controlled is also unknown, but clues are beginning to emerge and it is a very exciting time to be working in this field.

It is therefore particularly well-timed of Humana Press to release *Nuclear Reprogramming: Methods and Protocols* devoted to research techniques in nuclear reprogramming. I hope that this book will be of interest to a variety of people, be they cloners interested in the generation of live animals from cells, perhaps endangered species, or medics interested in the generation of stem cells or other cell types for therapeutic purposes, or biochemists or molecular biologists interested in the mechanism of the reprogramming process itself. This volume includes chapters describing various methods of nuclear reprogramming, including nuclear transfer in several different species, both amphibian and mammalian; fusion achieved both by chemical treatment and by electrically shocking cells; quantitative fusion and reprogramming by in vitro treatment of cells with cell extracts. Isolation of an adult stem-cell type is included. Several different methods of monitoring nuclear reprogramming are described, including the use of transgenic markers to follow reprogramming after nuclear transfer, activation of telomerase as an ES-specific marker, observation of structural changes in the nucleus by both light and electron microscopy, and verification of stem cells’ surface marker expression and differentiation potential. With respect to the biochemistry of nuclear reprogramming, methods for the examination of chromatin protein modifications,

nucleosomal footprinting, and transcription factor binding are included here, as are methods for the study of DNA methylation changes both at the specific locus level and, by microscopy, at the level of the whole nucleus.

I have enjoyed working on this project and I wish to take the opportunity here to express my gratitude to John Walker for the invitation to compile and edit this book, to Tom Lanigan and his team at Humana Press, and to the many scientists who have generously contributed chapters to this volume.

Steve Pells

Contents

Preface	v
Contributors	xi
1 Nuclear Transplantation in <i>Xenopus</i> John B. Gurdon	1
2 Nuclear Transfer in Sheep William A. Ritchie	11
3 Protocols for Nuclear Transfer in Mice Shaorong Gao	25
4 Isolation of Stromal Stem Cells From Human Adipose Tissue Andrew C. Boquest, Aboulghassem Shahdadfar, Jan E. Brinchmann, and Philippe Collas	35
5 Nuclear Reprogramming by Cell Fusion Robert H. Broyles, Austin C. Roth, Mairead Todd, and Visar Belegu	47
6 Polyethylene Glycol-Mediated Cell Fusion Jian Yang and Ming Hong Shen	59
7 Epigenetic Reprogramming of Somatic Genomes by Electrofusion With Embryonic Stem Cells Masako Tada and Takashi Tada	67
8 Quantification of Cell Fusion by Flow Cytometry Stephen Sullivan, Martin Waterfall, Ed J. Gallagher, Jim McWhir, and Steve Pells	81
9 Modulation of Cell Fate Using Nuclear and Cytoplasmic Extracts Anne-Mari Håkelién, Kristine G. Gaustad, and Philippe Collas	99
10 Transgenic Systems in Nuclear Reprogramming Megan Munsie, Peter Mountford, and Jennifer Nichols	115
11 Using Immunofluorescence to Observe Methylation Changes in Mammalian Preimplantation Embryos Fátima Santos and Wendy Dean	129
12 Observing S-Phase Dynamics of Histone Modifications With Fluorescently Labeled Antibodies Rong Wu, Anna V. Terry, and David M. Gilbert	139

13	Quantitative Analysis of Telomerase Activity and Telomere Length in Domestic Animal Clones Dean H. Betts, Steven Perrault, Lea Harrington, and W. Allan King	149
14	Pluripotency: <i>Capacity for In Vitro Differentiation of Undifferentiated Embryonic Stem Cells</i> Cornelia Wiese, Gabriela Kania, Alexandra Rolletschek, Przemyslaw Blyszczuk, and Anna M. Wobus	181
15	Staining Embryonic Stem Cells Using Monoclonal Antibodies to Stage-Specific Embryonic Antigens Bruce A. Fenderson, Maria P. De Miguel, April D. Pyle, and Peter J. Donovan	207
16	Analysis of the Nucleolar Compartment of the Nucleus as an Indicator of Nuclear Reprogramming After Nuclear Transfer Jacques-E. Fléchon	225
17	Methylation-Sensitive Polymerase Chain Reaction Hannah R. Moore, Richard R. Meehan, and Lorraine E. Young	239
18	Analysis of DNA Methylation Profiles in Preimplantation Embryos Using Bisulfite Mutagenesis Yong-Mahn Han, Seok-Ho Kim, and Yong-Kook Kang	251
19	Chromatin Immunoprecipitation Assay for Mammalian Tissues Fiona B. Turner, Wang L. Cheung, and Peter Cheung	261
20	Histone Modifications and Transcription Factor Binding on Chromatin: <i>ChIP-PCR Assays</i> Jaejoon Won and Tae Kook Kim	273
21	In Vivo Genomic Footprinting Using LM-PCR Methods Hiromi Tagoh, Peter N. Cockerill, and Constanze Bonifer	285
22	Analyzing Histone Modification Using Crosslinked Chromatin Treated With Micrococcal Nuclease Pascal Lefevre and Constanze Bonifer	315
	Index	327

Contributors

VISAR BELEGU • *Kennedy Krieger Institute, Johns Hopkins University, Baltimore, MD*

DEAN H. BETTS • *Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada*

PRZEMYSŁAW BLYSZCZUK • *In Vitro Differentiation Group, Institute of Plant Genetics and Crop Plant Research (IPK), Gatersleben, Germany*

CONSTANZE BONIFER • *Molecular Medicine Unit, University of Leeds; St. James's University Hospital, Leeds, United Kingdom*

ANDREW C. BOQUEST • *Institute of Medical Biochemistry, University of Oslo, Oslo, Norway*

JAN E. BRINCHMANN • *Institute of Immunology, Rikshospitalet University Hospital and University of Oslo, Oslo, Norway*

ROBERT H. BROYLES • *Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK*

PETER CHEUNG • *Department of Medical Biophysics, University of Toronto; Ontario Cancer Institute, Toronto, Ontario, Canada.*

WANG L. CHEUNG • *Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD*

PETER N. COCKERILL • *Molecular Medicine Unit, University of Leeds, St. James's University Hospital, Clinical Sciences Building, Leeds, United Kingdom*

PHILIPPE COLLAS • *Institute of Medical Biochemistry, University of Oslo, Oslo, Norway*

WENDY DEAN • *Laboratory of Developmental Genetics and Imprinting, The Babraham Institute, Cambridge, United Kingdom*

MARIA P. DE MIGUEL • *Cell Therapy Laboratory, La Paz Hospital, Madrid, Spain; Institute for Cell Engineering, The Johns Hopkins University, Baltimore, MD*

PETER J. DONOVAN • *Institute for Cell Engineering, The Johns Hopkins University, Baltimore, MD*

BRUCE A. FENDERSON • *Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University; Jefferson Medical College, Philadelphia, PA*

JACQUES-E. FLÉCHON • *Biologie du Développement et Reproduction, INRA, Jouy en Josas, France*

ED J. GALLAGHER • *MRC Technology, Western General Hospital, Edinburgh, United Kingdom*

SHAORONG GAO • *Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia PA*

- KRISTINE G. GAUSTAD • *Institute of Medical Biochemistry, University of Oslo, Oslo, Norway*
- DAVID M. GILBERT • *Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY*
- JOHN B. GURDON • *Wellcome Trust/Cancer Research United Kingdom Gurdon Institute, Cambridge, United Kingdom*
- ANNE-MARI HÅKELIEN • *Institute of Medical Biochemistry, University of Oslo, Oslo, Norway*
- YONG-MAHN HAN • *Laboratory of Development and Differentiation, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea*
- LEA HARRINGTON • *The Department of Medical Biophysics, The University of Toronto; Princess Margaret Hospital, Toronto, Ontario, Canada*
- GABRIELA KANIA • *In Vitro Differentiation Group, Institute of Plant Genetics and Crop Plant Research (IPK), Gatersleben, Germany*
- YONG-KOOK KANG • *Laboratory of Development and Differentiation, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon Korea*
- SEOK-HO KIM • *Laboratory of Development and Differentiation, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea*
- TAE KOOK KIM • *Department of Biological Sciences, Korea Advanced Institute of Science and Technology; Biomedical Research Center, Daejeon, South Korea; Harvard Cancer Center, Harvard Medical School, Boston, MA*
- W. ALLAN KING • *Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph Ontario, Canada*
- PASCAL LEFEVRE • *University of Leeds, St. James's University Hospital, Clinical Sciences Building, Molecular Medicine Unit, Leeds United Kingdom*
- JIM McWHIR • *Department of Gene Function and Development, Roslin Institute, Roslin, Midlothian, United Kingdom*
- RICHARD R. MEEHAN • *Department of Biomedical and Clinical Laboratory Sciences, University of Edinburgh, Edinburgh; Human Genetics Unit, MRC, Western General Hospital, Edinburgh, United Kingdom*
- HANNAH R. MOORE • *Division of Gene Function and Development, Roslin Institute, Roslin United Kingdom; and Department of Biomedical and Clinical Laboratory Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, United Kingdom; and Wellcome Centre for Cell Biology, University of Edinburgh, Swann Building, Kings Buildings, Edinburgh, United Kingdom*

- PETER MOUNTFORD • *Stem Cell Sciences Ltd, Collingwood, Victoria, Australia*
- MEGAN MUNSIE • *Stem Cell Sciences Ltd, Collingwood, Victoria, Australia*
- JENNIFER NICHOLS • *Centre Development in Stem Cell Biology, Institute for Stem Cell Research, University of Edinburgh, Edinburgh, United Kingdom*
- STEVE PELLIS • *Department of Gene Function and Development, Roslin Institute, Roslin, Midlothian, United Kingdom*
- STEVEN PERRAULT • *Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada*
- APRIL D. PYLE • *The Johns Hopkins University, Institute for Cell Engineering, Baltimore, MD*
- WILLIAM A. RITCHIE • *Department of Gene Function and Development, Roslin Institute, Roslin, Midlothian, United Kingdom*
- ALEXANDRA ROLLETSCHEK • *In Vitro Differentiation Group, Institute of Plant Genetics and Crop Plant Research (IPK), Gatersleben, Germany*
- AUSTIN C. ROTH • *Free Radical Biology and Aging Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK*
- FÁTIMA SANTOS • *Laboratory of Developmental Genetics and Imprinting, The Babraham Institute, Cambridge, United Kingdom*
- ABOULGHASSEM SHAHDADFAR • *Institute of Immunology Rikshospitalet University Hospital and University of Oslo, Rikshospitalet, Oslo, Norway*
- MING HONG SHEN • *MRC Human Genetics Unit, Western General Hospital, Edinburgh, United Kingdom*
- STEPHEN SULLIVAN • *Wellcome Trust/Cancer Research United Kingdom Gurdon Institute of Cancer and Developmental Biology, University of Cambridge, Cambridge, United Kingdom*
- MASAKO TADA • *ReproCELL Inc., Tokyo; Stem Cell Engineering, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan*
- TAKASHI TADA • *Stem Cell Engineering, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan*
- HIROMI TAGOH • *Molecular Medicine Unit, St. James's University Hospital, University of Leeds, Leeds United Kingdom*
- ANNA V. TERRY • *Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY*
- MAIREAD TODD • *Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK*
- FIONA B. TURNER • *Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA*
- MARTIN WATERFALL • *Scottish Stem Cell Network Sorting Facility, Roslin Institute, Roslin, Midlothian, United Kingdom*

- CORNELIA WIESE • *In Vitro Differentiation Group, Institute of Plant Genetics and Crop Plant Research (IPK), Gatersleben, Germany*
- ANNA M. WOBUS • *In Vitro Differentiation Group, Institute of Plant Genetics and Crop Plant Research (IPK), Gatersleben, Germany*
- JAEJOON WON • *Biomedical Research Center, Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, South Korea*
- RONG WU • *Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY*
- JIAN YANG • *Institute for Stem Cell Research, University of Edinburgh, Edinburgh, United Kingdom*
- LORRAINE E. YOUNG • *Division of Obstetrics and Gynaecology and Institute of Genetics, University of Nottingham, Queens Medical Centre, Nottingham, United Kingdom*